Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carles Codony

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Translational Lung Cancer Research|September 27, 2019
Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell linesJordi Codony-Servat, Santiago Viteri, Carles Codony-Servat, et al.
Oncotarget|May 19, 2017
Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)Carles Codony-Servat, Jordi Codony-Servat, Niki Karachaliou, et al.
International Journal of Molecular Sciences|July 14, 2023
SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell TherapyJuan José Soto-Castillo, Lucía Llavata-Marti, Roser Fort-Culillas, et al.
Cell Communication and Signaling : CCS|October 30, 2019
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinomaMasaoki Ito, Carles Codony-Servat, Jordi Codony-Servat, et al.
Nature Communications|April 20, 2019
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapyJordi Bertran-Alamillo, Valérie Cattan, Marie Schoumacher, et al.
Nature Communications|September 6, 2017
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancerKirstine Jacobsen, Jordi Bertran-Alamillo, Miguel Angel Molina, et al.
Translational Lung Cancer Research|November 19, 2020
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancerIlaria Attili, Laura Bonanno, Niki Karachaliou, et al.
Future Oncology (London, England)|August 12, 2024
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS studyJuan Martin-Liberal, Elena Garralda, Jesús García-Donas, et al.
Ebiomedicine|February 14, 2018
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor PrognosisNiki Karachaliou, Imane Chaib, Andres Felipe Cardona, et al.
Scientific Reports|December 8, 2015
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerNiki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Translational Lung Cancer Research|September 27, 2019
Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell linesJordi Codony-Servat, Santiago Viteri, Carles Codony-Servat, et al.
Oncotarget|May 19, 2017
Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)Carles Codony-Servat, Jordi Codony-Servat, Niki Karachaliou, et al.
International Journal of Molecular Sciences|July 14, 2023
SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell TherapyJuan José Soto-Castillo, Lucía Llavata-Marti, Roser Fort-Culillas, et al.
Cell Communication and Signaling : CCS|October 30, 2019
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinomaMasaoki Ito, Carles Codony-Servat, Jordi Codony-Servat, et al.
Nature Communications|April 20, 2019
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapyJordi Bertran-Alamillo, Valérie Cattan, Marie Schoumacher, et al.
Nature Communications|September 6, 2017
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancerKirstine Jacobsen, Jordi Bertran-Alamillo, Miguel Angel Molina, et al.
Translational Lung Cancer Research|November 19, 2020
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancerIlaria Attili, Laura Bonanno, Niki Karachaliou, et al.
Future Oncology (London, England)|August 12, 2024
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS studyJuan Martin-Liberal, Elena Garralda, Jesús García-Donas, et al.
Ebiomedicine|February 14, 2018
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor PrognosisNiki Karachaliou, Imane Chaib, Andres Felipe Cardona, et al.
Scientific Reports|December 8, 2015
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerNiki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, et al.
Pageof 3